Observational Cohort of COVID-19 Patients in Hubei Province

NCT05615792 | Completed

• 1 other identifier: TJ-COVID
• Study Type: observational
• Target: 68,000
• Locations: 1 country
• Sites: 1

Brief Summary

This study intends to use the relevant case data of COVID-19 in Hubei Province, using big data processing and mining methods to evaluate the effects of clinical indicators, drug use and genes on the clinical prognosis of COVID-19 patients, so as to provide a theoretical basis for the treatment of these diseases and reduce the mortality.

Conditions

2019 Novel Coronavirus Disease

Keywords

COVID-19; SARS-CoV-2; Risk Factors; Mortality

Outcome Measures

Primary Outcomes (1)

• All-cause mortality

  Numbers and dates of death in each group

  2 years

Study Arms (1)

patients with coronavirus disease 2019 (COVID-19)

Patients diagnosed with COVID-19 in Hubei Province

Other: No intervention

Interventions

No intervention OTHER

No intervention

patients with coronavirus disease 2019 (COVID-19)

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

This study is a hospital-based observational study initiated by Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology. Trained researchers are responsible for screening and joining the group. About 6,8000 COVID-19 patients in Hubei Province were expected to be included in this study. Patients enrolled in the group will undergo baseline survey and follow-up according to the program.

You may qualify if:

• Age ≥ 18, regardless of gender;
• A history of epidemiology, including travel or residence in high-risk areas or other communities with case reports within 14 days before the onset of the disease, or have a history of contact with novel coronavirus infection (those who are positive for nucleic acid tests); or patients with fever or respiratory symptoms from the community with case reports; or aggregative onset;
• Corresponding clinical manifestations, including respiratory symptoms such as fever, with typical imaging features of COVID-19, normal or decreased white blood cell count and decreased lymphocyte count in the early stage of the disease;
• Clear etiological evidence, including real-time fluorescent RT-PCR detection of novel coronavirus nucleic acid positive, or viral gene sequencing, is highly homologous to novel coronavirus.

You may not qualify if:

• Patients who meet any of the following criteria cannot be enrolled in this study:
• Patients refused to participate in this study;
• According to the researchers, patients are unable to complete this study or comply with the requirements of this study (due to management or other reasons).

Sponsors & Collaborators

• Dao Wen Wang: lead

Study Sites (1)

Tongji Hospital

Wuhan, Hubei, 430030, China

Location

Related Publications (2)

• Li D, He W, Yu B, Wang DW, Ni L. NT-proBNP ratio is a potential predictor for COVID-19 outcomes in adult Chinese patients: a retrospective study. Sci Rep. 2024 Mar 11;14(1):5906. doi: 10.1038/s41598-024-56329-2.

  PMID: 38467760 DERIVED

• Xu K, He W, Yu B, Zhong K, Zhou D, Wang DW. Beneficial Effects of Angiotensin II Receptor Blockers on Mortality in Patients with COVID-19: A Retrospective Study from 2019 to 2020 in China. Cardiovasc Drugs Ther. 2025 Feb;39(1):63-74. doi: 10.1007/s10557-023-07494-5. Epub 2023 Aug 11.

  PMID: 37566218 DERIVED

MeSH Terms

Conditions

COVID-19

Condition Hierarchy (Ancestors)

Pneumonia, Viral; Pneumonia; Respiratory Tract Infections; Infections; Virus Diseases; Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Lung Diseases; Respiratory Tract Diseases

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Prof.

Study Record Dates

• First Submitted: November 10, 2022
• First Posted: November 14, 2022
• Study Start: February 1, 2020
• Primary Completion: March 1, 2024
• Study Completion: March 1, 2024
• Last Updated: March 7, 2024

Record last verified: 2024-03

Locations

CN (1)